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Introduction
Mass spectrometry (MS)-based proteomics is a uniquely 
powerful  and  versatile  tool  in  biology  as  it  allows  un-
biased, comprehensive and sensitive detection of proteins 
and post-translational protein modifications in complex 
mixtures.  With  the  ability  to  identify  thousands  of 
proteins  in  a  single  experiment,  MS-based  proteomics 
makes it easy to generate lengthy protein catalogs, but 
quali  tative comparisons of lists of proteins is less infor-
mative.  Instead,  the  ability  to  quantify  abundances  of 
whole  proteomes  and  to  observe  these  changing  over 
time or in response to a defined perturbation would be 
very powerful. Such information can be obtained with 
quantitative  proteomics,  which  greatly  enhances  the 
power and utility of MS-based methods [1,2].
MS measures and distinguishes analytes by their masses. 
The  more  robust  and  accurate  quantification  methods 
use stable isotopes such as 13C, 15N and 18O to introduce a 
detectable  increase  in  mass.  Except  for  the  increased 
mass  from  the  additional  neutrons,  the  stable  isotope 
labeled (SIL) internal standard and the analyte are essen-
tially indistinguishable. Comparing MS peak signal inten-
si  ties from samples containing unlabeled ‘light’ and SIL 
‘heavy’  peptides  quantifies  relative  protein  abun  dance. 
Minimizing  physicochemical  differences  between  the 
analyte and the internal standard allows analytical work-
flows to be combined and reduces experimental errors in 
quantification.
The  toolbox  for  quantitative  proteomics  continues  to 
expand, providing many options for researchers. Recently, 
Mann  and  co-workers  described  an  approach  based  on 
stable  isotope  labeling  by  amino  acids  in  cell  culture 
(SILAC) [3] that combines multiple cellular proteomes to 
obtain  whole  proteome  SIL  standards  suitable  for  the 
quantification of the complex tissue proteomes that are 
typical in clinical proteomics [4].
Pooling proteomes as internal standards
For  over  two  decades,  researchers  have  spiked  peptides 
stably labeled with isotopes into samples and quantified 
these  reference  standards  against  their  endogenous 
counter  parts to measure protein levels. This approach to 
quantifying  small  numbers  of  analytes  from  complex 
peptide mixtures with targeted MS assays has grown in 
popularity  for  studying  specific  protein  classes,  such  as 
kinases [5], and especially as a platform for the validation 
of  candidate  biomarkers  in  clinical  samples  (Figure  1a) 
[6,7]. Alternatively, faster peptide sequencing capabilities 
in modern MS instruments enable approaches combining 
peptide identification and quantification to provide whole-
proteome analysis of differential protein expression. Stable 
isotope labels are introduced in entire proteomes through 
chemical derivatization with SIL tags [8,9] or metabolic 
labeling with essential metabolites such as SIL amino acids 
[3].  The  latter  approach,  requiring  living  cells,  is  often 
thought to be incompatible with tissue proteomics.
Abstract
As mass-spectrometry-based quantitative proteomics 
approaches become increasingly powerful, 
researchers are taking advantage of well established 
methodologies and improving instrumentation to 
pioneer new protein expression profiling methods. For 
example, pooling several proteomes labeled using the 
stable isotope labeling by amino acids in cell culture 
(SILAC) method yields a whole-proteome stable 
isotope-labeled internal standard that can be mixed 
with a tissue-derived proteome for quantification. 
By increasing quantitative accuracy in the analysis 
of tissue proteomes, such methods should improve 
integration of protein expression profiling data 
with transcriptomic data and enhance downstream 
bioinformatic analyses. An accurate and scalable 
quantitative method to analyze tumor proteomes at 
the depth of several thousand proteins provides a 
powerful tool for global protein quantification of tissue 
samples and promises to redefine our understanding 
of tumor biology.
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analysis of its molecular components and is probably the 
central  challenge  in  comprehensive  analyses  of  tissue 
proteomes. Despite the difficulties, our understanding of 
disease biology could be greatly enhanced by improved 
methods to accurately profile global protein expression in 
tissue samples, such as patient tumor biopsies. Clinical 
tissue  proteomics  currently  lags  behind  proteomics  in 
other  areas,  such  as  model  organisms  or  cell  culture-
based systems, particularly in quantitative comparisons 
of protein abundance between tissue samples. An impor-
tant application in clinical proteomics is the identification 
of protein biomarkers in samples from diseased versus 
unaffected people [7]. These clinical samples may be from 
tumor  tissue  or  biological  fluids  near  affected  sites. 
Biomarker  studies  commonly  apply  a  staged  approach: 
initial discovery of highly differentially expressed proteins 
followed  by  more  careful  validation  with  spiked  SIL 
internal  standards  to  quantify  specific  proteins.  In  the 
discovery phase, it is possible to use chemical labeling 
strategies (Figure 1b) to compare six or up to eight tissue 
samples  simultaneously  with  the  commercial  reagents 
tandem mass tags (TMT) [9] or the isobaric tag for rela-
tive and absolute quantification (iTRAQ) [8], respectively. 
Figure 1. Quantitative approaches in profiling complex tissue proteomes. (a) Quantification using exogenous stable isotope labeled (SIL) 
peptide standards. The sample to be analyzed is common to both forks in the workflow and is marked in the dotted box. Tissue samples are 
processed to extract proteins and digested with trypsin to generate complex mixtures of peptides. In a targeted MRM-based assay (left) [6,7], 
known amounts of chemically synthesized SIL peptides matching peptides from target proteins are introduced to the sample and serve as relative 
internal standards in peptide quantification. In an alternative workflow (right), pools of SILAC-labeled cells are combined; extracted proteins 
are digested with the same enzyme (trypsin) to generate a whole-proteome SIL peptide standard containing tens of thousands to hundreds 
of thousands of peptides [4]. This SIL proteome standard can be adjusted to match the cellular characteristics of the sample to be quantified. 
A large stock of a suitable proteome standard could be a common internal reference spiked into hundreds of experiments. (b) Quantification by 
derivatizing peptides with chemical labeling reagents. This is currently the most common approach for SIL-based quantification of whole-tissue 
proteomes. Peptides are tagged with chemical labels directed to specific functional groups, such as primary amines of the amino terminus and 
lysine residues. Commercially available reagents such as iTRAQ and TMT allow multiplexing of samples (up to eight with iTRAQ), but this may be a 
limiting factor if larger studies are desired.
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tative  measures  such  as  spectral  counts  [10]  or  total 
peptide signal intensity from identified peptides to deter-
mine differential expression [11,12]. Because of the larger 
variances in these semi-quantitative measure  ments, only 
very  differentially  expressed  proteins  are  selected  for 
downstream validation experiments, such as quantitative 
multiple reaction monitoring (MRM)-MS assays.
The approach of Mann and coworkers [4] may bridge 
the gap between the stages of initial discovery and MRM-
MS validation of candidate biomarkers. They pooled five 
different  SILAC-labeled  breast  cancer  cell  lines  to 
generate a superset of SIL peptides derived from their 
combined proteomes. The large collection of peptides in 
the  super-SILAC  mix  was  then  applied  as  internal 
standards to quantify proteins in breast and brain tumor 
samples.  Their  work  [4]  builds  on  earlier  work  from 
Ishihama  et  al.  [13]  in  which  a  single  SILAC-labeled 
neuro  blastoma  cell  line  was  used  to  quantify  protein 
expression in mouse brain. Because the whole-proteome 
SIL standard is derived from multiple cell lines, it pro-
vides a diverse pool of proteins that can be adjusted to 
more accurately represent the heterogeneous cell popula-
tions of a particular tumor sample, thus increasing the 
likelihood that a tumor-derived peptide will have a heavy 
SIL counterpart for accurate quantification. Geiger et al. 
[4] achieved high quantitative coverage, quantifying over 
70%  of  identified  proteins  in  both  tumor  samples  and 
improving overall quantitative accuracy through the use 
of the pooled SILAC cell lines when compared with a 
single labeled cell line.
There are several practical advantages: SILAC labeling 
is  inexpensive  and  several  million  cells  can  yield 
milligrams of SIL internal standards, material sufficient 
for hundreds of experiments. Although the authors [4] 
pooled  only  carcinoma  cell  lines,  combining  a  more 
diverse collection of SILAC labeled cell lines and mixing 
these at different levels might better mimic the hetero-
geneity of cell types in a tumor. Quantitative accuracy 
would then be substantially better, as a greater number of 
SIL peptides would serve as internal standards for quanti-
fication or be available as ‘landmarks’ in normalization 
and sample matching [13,14]. The super-SILAC approach 
is  scalable  and  flexible,  allowing  the  generation  of 
reference  libraries  of  SIL  peptides  that  can  be  applied 
over the duration of a lengthy biomarker discovery cam-
paign, spanning different tissue types and sample sources. 
Improved  quantification  of  complex  tissue  proteomic 
samples  in  the  discovery  phase  could  substantially 
improve confidence in the identification of differentially 
expressed proteins, effectively triaging the long lists of 
candidate biomarkers requiring validation.
Not surprisingly, spiking in a whole proteome’s worth 
of  SIL  peptides  brings  new  analytical  challenges.  The 
combined  super-SILAC  and  tumor  proteome  mixture 
will  have  at  least  doubled  in  complexity,  and  the 
dynamic range of accurate peptide quantification may 
not span the full range of analytes of interest. Indeed, 
the  whole-proteome  SIL  standard  is  unlikely  to  be 
useful in the valida  tion phase of biomarker discovery. 
Interfering  signals  from  unrelated  peptide  species 
compromise MRM-MS assays, requiring the monitoring 
of  multiple  peptide  precursor-fragment  transitions  to 
increase  specificity  when  quantifying  a  particular 
peptide analyte. Adding hundreds of thousands of SIL 
peptides  for  MRM  assays  is  unnecessary  because 
experiments target specific peptides and doing so will 
have  only  a  negative  impact  on  quantitative  accuracy 
and specificity.
Conclusions
There is relatively little collective experience in defining 
protein expression profiles from biomarker studies. There 
are few published biomarker discovery datasets and even 
fewer  in  public  data  repositories,  in  stark  contrast  to 
widely  available  microarray  and  next-generation  high-
throughput genomic data. We do not yet have common 
protocols for processing protein samples similar to those 
well  established  in  transcript  profiling  experiments. 
Proteins cannot be amplified with powerful PCR-based 
methods and, compared with mRNA, proteins are less 
homogeneous  and  require  more  care  in  handing  and 
extraction. Many current datasets of biomarker protein 
expression  profiles  use  semi-quantitative  measures  of 
protein  abundance;  large  variations  in  these  profiles 
complicate  attempts  to  extract  meaningful  hypotheses 
and  limit  their  overall  utility.  The  researcher  has  little 
choice but to attribute quantitative variation to biological 
noise and sample variability and only select proteins with 
the  most  significant  expression  differences  for  down-
stream validation experiments.
The complexities of tumor biology may well turn out 
to  be  the  limiting  factor  in  our  attempts  to  make 
molecular profiles of cancer, but it is certainly harder to 
argue against better analytical tools. Greater quantitative 
accuracy, afforded by the use of a super-SILAC proteome 
standard or other means, will undoubtedly improve the 
quality  of  tissue  protein  expression  profiles  and  our 
ability to confidently identify subtle changes in protein 
expression.  Widespread  use  of  whole-proteome  SIL 
stan  dards  may  provide  a  framework,  similar  to 
approaches commonly used in gene expression profiling 
[15],  to  standardize  quantitative  analyses  of  complex 
tissue  samples  in  clinical  proteomics.  The  ability  to 
robustly compare different clinical proteomics datasets 
would  facilitate  the  integration  of  datasets  from 
proteomics  and  genomics  and  transform  the  field  of 
clinical proteomics.
Ong Genome Medicine 2010, 2:49 
http://genomemedicine.com/content/2/7/49
Page 3 of 4Abbreviations
iTRAQ, isobaric tag for relative and absolute quantification; MRM, multiple 
reaction monitoring; MS, mass spectrometry; SIL, stable isotope labeled/
labeling; SILAC, stable isotope labeling by amino acids in cell culture; TMT, 
tandem mass tag.
Competing interests
The author declares that they have no competing interests.
Published: 30 July 2010
References
1.  Gstaiger M, Aebersold R: Applying mass spectrometry-based proteomics to 
genetics, genomics and network biology. Nat Rev Genet 2009, 10:617-627.
2.  Ong SE, Mann M: Mass spectrometry-based proteomics turns quantitative. 
Nat Chem Biol 2005, 1:252-262.
3.  Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, Mann 
M: Stable isotope labeling by amino acids in cell culture, SILAC, as a simple 
and accurate approach to expression proteomics. Mol Cell Proteomics 2002, 
1:376-386.
4.  Geiger T, Cox J, Ostasiewicz P, Wisniewski JR, Mann M: Super-SILAC mix for 
quantitative proteomics of human tumor tissue. Nat Methods 2010, 
7:383-385.
5.  Picotti P, Rinner O, Stallmach R, Dautel F, Farrah T, Domon B, Wenschuh H, 
Aebersold R: High-throughput generation of selected reaction-monitoring 
assays for proteins and proteomes. Nat Methods 2010, 7:43-46.
6.  Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, 
Spiegelman CH, Zimmerman LJ, Ham AJ, Keshishian H, Hall SC, Allen S, 
Blackman RK, Borchers CH, Buck C, Cardasis HL, Cusack MP, Dodder NG, 
Gibson BW, Held JM, Hiltke T, Jackson A, Johansen EB, Kinsinger CR, Li J, Mesri 
M, Neubert TA, Niles RK, Pulsipher TC, Ransohoff D, et al.: Multi-site 
assessment of the precision and reproducibility of multiple reaction 
monitoring-based measurements of proteins in plasma. Nat Biotechnol 
2009, 27:633-641.
7.  Rifai N, Gillette MA, Carr SA: Protein biomarker discovery and validation: the 
long and uncertain path to clinical utility. Nat Biotechnol 2006, 24:971-983.
8.  Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski 
N, Pillai S, Dey S, Daniels S, Purkayastha S, Juhasz P, Martin S, Bartlet-Jones M, 
He F, Jacobson A, Pappin DJ: Multiplexed protein quantitation in 
Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. 
Mol Cell Proteomics 2004, 3:1154-1169.
9.  Thompson A, Schafer J, Kuhn K, Kienle S, Schwarz J, Schmidt G, Neumann T, 
Johnstone R, Mohammed AK, Hamon C: Tandem mass tags: a novel 
quantification strategy for comparative analysis of complex protein 
mixtures by MS/MS. Anal Chem 2003, 75:1895-1904.
10.  Liu H, Sadygov RG, Yates JR 3rd: A model for random sampling and 
estimation of relative protein abundance in shotgun proteomics. Anal 
Chem 2004, 76:4193-4201.
11.  Griffin NM, Yu J, Long F, Oh P, Shore S, Li Y, Koziol JA, Schnitzer JE: Label-free, 
normalized quantification of complex mass spectrometry data for 
proteomic analysis. Nat Biotechnol 2010, 28:83-89.
12.  Negishi A, Ono M, Handa Y, Kato H, Yamashita K, Honda K, Shitashige M, 
Satow R, Sakuma T, Kuwabara H, Omura K, Hirohashi S, Yamada T: Large-scale 
quantitative clinical proteomics by label-free liquid chromatography and 
mass spectrometry. Cancer Sci 2009, 100:514-519.
13.  Ishihama Y, Sato T, Tabata T, Miyamoto N, Sagane K, Nagasu T, Oda Y: 
Quantitative mouse brain proteomics using culture-derived isotope tags 
as internal standards. Nat Biotechnol 2005, 23:617-621.
14.  Mueller LN, Rinner O, Schmidt A, Letarte S, Bodenmiller B, Brusniak MY, Vitek 
O, Aebersold R, Muller M: SuperHirn - a novel tool for high resolution 
LC-MS-based peptide/protein profiling. Proteomics 2007, 7:3470-3480.
15.  Dozmorov I, Lefkovits I: Internal standard-based analysis of microarray data. 
Part 1: analysis of differential gene expressions. Nucleic Acids Res 2009, 
37:6323-6339.
doi:10.1186/gm170
Cite this article as: Ong S-E: Whole proteomes as internal standards in 
quantitative proteomics. Genome Medicine 2010, 2:49.
Ong Genome Medicine 2010, 2:49 
http://genomemedicine.com/content/2/7/49
Page 4 of 4